BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 18625380)

  • 1. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
    Weger W; Kränke B; Gerger A; Salmhofer W; Aberer E
    J Am Acad Dermatol; 2008 Aug; 59(2 Suppl 1):S4-6. PubMed ID: 18625380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine-induced subacute cutaneous lupus erythematosus: report of a case with positive rechallenge test.
    Ko JH; Hsieh CI; Chou CY; Wang KH
    J Dermatol; 2013 Nov; 40(11):939-40. PubMed ID: 24111883
    [No Abstract]   [Full Text] [Related]  

  • 3. Subacute cutaneous lupus erythematosus induced by capecitabine.
    Floristan U; Feltes RA; Sendagorta E; Feito-Rodriguez M; Ramírez-Marín P; Vidaurrázaga C; Casado-Jiménez M
    Clin Exp Dermatol; 2009 Oct; 34(7):e328-9. PubMed ID: 19456774
    [No Abstract]   [Full Text] [Related]  

  • 4. Subacute cutaneous lupus erythematosus after treatment with capecitabine.
    Kindem S; Llombart B; Requena C; Ruiz A; Traves V; Guillen C; San Martin O
    J Dermatol; 2013 Jan; 40(1):75-6. PubMed ID: 22937906
    [No Abstract]   [Full Text] [Related]  

  • 5. Subacute cutaneous lupus erythematosus associated with capecitabine monotherapy.
    Fernandes NF; Rosenbach M; Elenitsas R; Kist JM
    Arch Dermatol; 2009 Mar; 145(3):340-1. PubMed ID: 19289781
    [No Abstract]   [Full Text] [Related]  

  • 6. [Capecitabine-induced subacute cutaneous lupus: a case report].
    Fongue J; Meunier B; Lardet D; Dicostanzo MP; Rouby F; Terrier JP; Harlé JR; Richard MA; Chiche L
    Ann Dermatol Venereol; 2014 Oct; 141(10):593-7. PubMed ID: 25288062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal melanonychia induced by capecitabine.
    Paravar T; Hymes SR
    Dermatol Online J; 2009 Oct; 15(10):11. PubMed ID: 19951629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Do JE; Kim YC
    Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
    Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
    Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of capecitabine in gastric cancer.
    Comella P; Franco L; Casaretti R; de Portu S; Menditto E
    Pharmacotherapy; 2009 Mar; 29(3):318-30. PubMed ID: 19249950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
    Seminara P; Losanno T; Emiliani A; Manna G
    Cardiology; 2010; 116(1):42-4. PubMed ID: 20431291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine: an overview of the side effects and their management.
    Saif MW; Katirtzoglou NA; Syrigos KN
    Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine.
    Ramani VS; Sun Myint A; Montazeri A; Wong H
    Colorectal Dis; 2010 Aug; 12 Suppl 2():37-46. PubMed ID: 20618366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature.
    Shakhbazova A; Marsch AF
    Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
    Petrioli R; Pascucci A; Francini E; Marsili S; Fiaschi AI; Civitelli S; Tanzini G; Battistelli S; Lorenzi M; Roviello F; Francini G;
    Anticancer Drugs; 2008 Jan; 19(1):91-6. PubMed ID: 18043134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
    Ajani J
    Cancer; 2006 Jul; 107(2):221-31. PubMed ID: 16770784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine induced colitis.
    Maggo G; Grover SC; Grin A
    Pathol Res Pract; 2014 Sep; 210(9):606-8. PubMed ID: 24947412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.